Arkolith/Insider Trading/CRVS/Form 4

Thompson Peter A.

Director, 10% OwnerCorvus Pharmaceuticals, Inc. (CRVS) · full profile →Form 4 · filed May 8, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 6, 2024Buy(P)1.4M——1.4M
May 6, 2024Buy(P)1.4M$1.73$2.5M1.4M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000947871-24-000451) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML